EUCTR2015-003930-28-DE进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects with Excessive sleepiness Due to Obstructive Sleep Apnea - OSA Driving Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, age 21 to 75 years inclusive
- •2. Diagnosis of obstructive sleep apnea (OSA) per ICSD-3
- •3. BMI 18 to <40 kg/m2
- •4. Use a medically acceptable method of contraception
- •5. Willing and able to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Female subjects who are pregnant, nursing, or lactating
- •2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness
- •3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia,schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria
- •4. History or presence of any unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy and/or safety assessments per the judgment of the investigator
- •5. History of bariatric surgery within the past year
- •6. Presence of significant cardiovascular disease
- •7. Use of any over-the-counter (OTC) or prescription medications that could affect sleep-wake function
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. aeruginosa in Cystic Fibrosis Subjects Aged from 3 Months to less than 7 years.EUCTR2009-016590-15-FRovartis Pharma Services AG51
进行中（未招募）
1 期
A clinical trial to evaluate the effects of JZP-110 (study drug) on driving performance in subjects with excessive sleepiness due to NarcolpesyTreatment of excessive sleepiness in adult patients with narcolepsyMedDRA version: 20.0Level: HLTClassification code 10028716Term: Narcolepsy and associated conditionsSystem Organ Class: 100000004873EUCTR2015-003931-36-DEJazz Pharmaceuticals Inc.24
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients with Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment with Immunosuppressants. - C08-001EUCTR2009-014669-13-GBAlexion Pharmaceuticals Inc.24
已完成
2 期
A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects with Excessive Sleepiness Due to NarcolepsyNarcolepsysleep disease10040998NL-OMON47913JAZZ Pharmaceuticals Inc.33
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metformin Treatment twice daily in Patients with Type 2 DiabetesType II Diabetes MellitusMedDRA version: 7Level: LLTClassification code 10045242EUCTR2005-004032-48-SEAstraZeneca AB36